GE HealthCare Technologies, Inc. (GEHC) is well-poised for growth in the coming quarters, courtesy of its continued focus on innovations. The optimism, led by strong second-quarter fiscal 2024 performance and acquisitions, is expected to contribute further. However, geopolitical tensions and stiff competition are concerning.This Zacks Rank #2 (Buy) company’s shares have risen 3.1% in the past six months compared with 6.7% growth of the industry. The S&P 500 composite has risen 6.9% during the said time fram ...

公司分析 - GE HealthCare Technologies (GEHC) 的 Zacks Rank 为 2 (Buy) 表明其盈利预测修正活动表现优异 分析师对其前景持乐观态度 [3] - Insulet (PODD) 的 Zacks Rank 为 3 (Hold) 表明其盈利预测修正活动相对较弱 [3] - GEHC 的远期市盈率 (P/E) 为 17.93 远低于 PODD 的 67.51 表明 GEHC 的估值更具吸引力 [5] - GEHC 的 PEG 比率为 2.76 低于 PODD 的 3.32 表明 GEHC 的盈利增长预期更佳 [5] - GEHC 的市净率 (P/B) 为 4.59 远低于 PODD 的 16.58 表明 GEHC 的账面价值更具吸引力 [6] - GEHC 的价值评分为 B 远高于 PODD 的 D 表明 GEHC 在价值投资方面更具优势 [6] 行业分析 - 医疗产品行业的投资者对 GE HealthCare Technologies (GEHC) 和 Insulet (PODD) 较为熟悉 [1] - 价值投资者通常通过分析市盈率 (P/E) 市销率 (P/S) 盈利收益率 每股现金流等关键指标来判断公司是否被低估 [4] - 价值投资者倾向于选择盈利预测修正趋势强劲且估值指标具有吸引力的公司 [2][4]

GE HealthCare Technologies Inc. GEHC shares are trading higher Wednesday. The stock was upgraded from Hold to Buy, while the price target was raised from $95 to $103 by Jefferies.But some traders and investors who hold shares may be selling them before they reach the $103 level. This is why it is our Stock of the Day.Successful traders don't guess. They let the market tell them what to do. They identify important price levels to determine where to place their orders.As you can see on the chart, the $94 leve ...

Since I last covered GE HealthCare (NASDAQ: GEHC ) in October 2023, its shares have gained nearly 27% as charted below. This upside contrasts with my hold position because while praising its AI-driven strategy and highlighting the value proposal, I had cautionedAs a tech-focused industry Research Analyst, I aim to provide differentiated insights, whether it is for investing, trading, or informational reasons. For this purpose, I am not a classical equity researcher from the financial sector, but, I come fro ...

GE HealthCare Technologies Inc. (GEHC) recently announced the 510(k) submission to the FDA for CleaRecon DL, a deep-learning technology. The company is looking to get FDA clearance for the technology designed to improve the quality of cone-beam computed tomography (CBCT) images by bringing artificial intelligence (AI)-based 3D reconstruction to the interventional suite.GE HealthCare is committed to assisting physicians in utilizing image guidance technologies to their maximum capacity by removing obstacles ...

GE HealthCare Technologies Inc. (GEHC) recently unveiled Sonic DL for 3D to further boost the company’s imaging portfolio. Sonic DL for 3D builds on GE HealthCare’s deep learning innovation legacy and the success of AIR Recon DL.By extending Sonic DL to 3D volumetric imaging, GE HealthCare is likely to expand its use beyond cardiac assessments to include brain, spine, orthopedic, and body exams. The goal of this expansion is to significantly cut scan times while maintaining the same remarkable 12 times scan ...

文章核心观点 - GE HealthCare Technologies Inc. (GEHC) 宣布与澳大利亚墨尔本的Peter MacCallum癌症中心合作，共同开发和探索其全身正电子发射断层扫描/计算机断层扫描（PET/CT）技术的临床和研究可能性 该技术采用128 cm的超高灵敏度探测器，预计将增强GEHC在癌症研究领域的地位，并提升其在全球细分市场的竞争力 [1][2] 公司合作与技术 - GEHC的PET/CT技术目前处于开发阶段，尚未上市，也未获得FDA或其他全球监管机构的商业可用性批准 [2] - 该技术旨在支持研究和提升传统PET的能力，推动新诊断和治疗药物的加入，开辟新的临床路径，支持现有的分子成像和治疗学应用，并提升医疗系统的效率 [7] - Peter MacCallum癌症中心认为GEHC的新PET/CT技术有望在一次扫描中完成从头部到大腿的成像，为研究创造新机会 结合深度学习能力，该技术可能成为患者的重要进步，支持预防、早期检测和更好地扫描晚期癌症 [8] 公司财务与市场表现 - GEHC目前市值为379.2亿美元，其收益率为5.2%，高于行业的1.8% 在最近一个季度，GEHC实现了7.6%的盈利惊喜 [4] - 自11月25日宣布合作以来，公司股价上涨了近0.7% 历史上，GEHC从各种合作中获得了高水平的协同效应，预计市场对该股票的情绪将继续保持积极 [3] - 过去一年，GEHC股价上涨了21.2%，而行业上涨了22.2%，标普500指数上涨了31.5% [12] 行业前景与市场潜力 - 根据世界卫生组织（WHO）的估计，到2050年，全球新癌症病例将达到3500万，比2022年的2000万增加了77% [5] - GEHC指出，全身PET/CT成像的需求和创新增加是由于其能够检测的疾病（主要是癌症）的增加 随着癌症发病率的上升，新的免疫疗法和药物的可用性也在增加，从而鼓励了更多个性化医疗实践的发展 其中一种增长中的实践是治疗学，它结合了成像技术（包括PET/CT）和靶向诊断与治疗，以识别和治疗疾病并监测患者对治疗的反应 [6] - 根据Precedence Research的报告，全球肿瘤市场规模在2024年为2250.1亿美元，预计到2034年将达到6682.6亿美元，年复合增长率为11.5% 技术进步和癌症发病率的增加预计将推动市场增长 鉴于市场潜力，最新的合作预计将为GEHC的业务提供显著推动 [9] 公司近期发展 - 本月，GEHC宣布了新的Pristina Via乳腺摄影系统，旨在增强技术人员和患者的筛查体验 [11] - 上个月，GEHC宣布了CareIntellect for Oncology，这是一个新的云优先应用程序，将来自不同系统的多模态患者数据整合到一个视图中，使用生成式AI总结临床笔记和报告 [11]

GE HealthCare Technologies Inc. (GEHC) recently unveiled the new Pristina Via mammography system. This system will provide mammography technologists with a suite of advanced tools that balance the demands of diagnostic accuracy and workflows to facilitate more patient-centered breast care.As GEHC continues to evolve its Senographe Pristina platform, Pristina Via brings advanced new features to help minimize repetitive tasks and streamline workflows so that mammography technologists can maintain their focus ...

GE HealthCare Technologies Inc. (GEHC) recently announced additional clinical applications of the OEC 3D mobile CBCT C-arm portfolio, which enable precise and efficient imaging during endoscopic bronchoscopy procedures in interventional pulmonology.For routine procedures like neuro-spine and orthopedic trauma, as well as interventional procedures like bronchoscopy, GE HealthCare's OEC 3D intraoperative mobile CBCT continues to show imaging superiority and versatility.Likely Trend of GEHC Stock Following the ...

DURHAM, NC and LONDON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s specialized MRI Chest Coil to now include GE HealthCare 3 Tesla (3T) MRI scanners for the visualization of Xenon-129 nuclei. With this new introduction, the Compa ...